SCHEMBL8889599

SCHEMBL8889599

C[C@@H](O)[C@@H](C)c1ccccc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.52
ADRA2C P18825 2/20 0.52
KDM4E B2RXH2 2/20 0.52
ADRA2A P08913 1/20 0.52
HIF1A Q16665 1/20 0.52
ALDH1A1 P00352 2/20 0.50
TSHR P16473 2/20 0.48
CHRM2 P08172 1/20 0.48
ADRA1A P35348 1/20 0.48
RGS12 O14924 1/20 0.48
GLA P06280 1/20 0.48
CYP3A4 P08684 1/20 0.48
CYP2D6 P10635 1/20 0.48
CYP2C9 P11712 1/20 0.48
PKM P14618 1/20 0.48
ALOX15 P16050 1/20 0.48
ALOX12 P18054 1/20 0.48
NFKB1 P19838 1/20 0.48
HTR2A P28223 1/20 0.48
CYP2C19 P33261 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrogen Peroxide SCHEMBL10892167 1.00 LMNA (0.52) LMNAADRA2CKDM4EADRA2AHIF1A
SCHEMBL17113746 1.00 LMNA (0.52) LMNAADRA2CKDM4EADRA2AHIF1A
SCHEMBL19725368 1.00 LMNA (0.52) LMNAADRA2CKDM4EADRA2AHIF1A
SCHEMBL611639 1.00 LMNA (0.52) LMNAADRA2CKDM4EADRA2AHIF1A
SCHEMBL17086641 1.00 LMNA (0.52) LMNAADRA2CKDM4EADRA2AHIF1A
SCHEMBL23626333 1.00 LMNA (0.52) LMNAADRA2CKDM4EADRA2AHIF1A
Ammonia Solution, Strong SCHEMBL7773660 0.97 LMNA (0.50) LMNAADRA2CKDM4EADRA2AHIF1A
SCHEMBL27533967 0.85 PTGS2 (0.55) LMNAALDH1A1CYP3A4CYP2D6CYP2C9
SCHEMBL28312135 0.84 LMNA (0.48) LMNAADRA2CKDM4EADRA2AHIF1A
SCHEMBL248773 0.83 LMNA (0.52) LMNAADRA2CKDM4EADRA2AHIF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2900223-B1 NOVEL COMPOUNDS THAT ARE ERK INHIBITORS MERCK SHARP & DOHME (US) 2017-10-25 EP disclosed
US-9546168-B2 ERK inhibitors MERCK SHARP & DOHME CORP. (US) 2017-01-17 US disclosed
US-9233979-B2 Compounds that are ERK inhibitors MERCK SHARP & DOHME CORP. (US) 2016-01-12 US disclosed
US-9226922-B2 Compounds that are ERK inhibitors MERCK SHARP & DOHME CORP. (US) 2016-01-05 US disclosed
US-20150266895-A1 NOVEL COMPOUNDS THAT ARE ERK INHIBITORS MERCK SHARP & DOHME CORP. (US) 2015-09-24 US disclosed
US-20150258074-A1 NOVEL COMPOUNDS THAT ARE ERK INHIBITORS MERCK SHARP & DOHME CORP. (US) 2015-09-17 US disclosed
US-20090312559-A1 CATALYTIC ENANTIOSELECTIVE SILYLATIONS OF SUBSTRATES NATIONAL INSTITUTES OF HEALTH, U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT 2009-12-17 US disclosed
US-5614522-A SULFONAMIDE AND UREA-CONTAINING HYDROXYETHYLAMINE COMPOUNDS G.D. SEARLE & CO. (US) 1997-03-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090312559-A1 CATALYTIC ENANTIOSELECTIVE SILYLATIONS OF SUBSTRATES LSS, COASY, CYP51A1 LMNA 1731/4885ADRA2C 1257/4885KDM4E 2266/4885
US-20150266895-A1 NOVEL COMPOUNDS THAT ARE ERK INHIBITORS MAPK1, MAPK10, MAP3K1 LMNA 4603/4885ADRA2C 3407/4885KDM4E 3001/4885
US-20150258074-A1 NOVEL COMPOUNDS THAT ARE ERK INHIBITORS MAPK1, MAPK4, MAP3K20 LMNA 4615/4885ADRA2C 2098/4885KDM4E 2166/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.